Corbus Pharmaceuticals to Report Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity on Thursday, December 11, 2025

Corbus Pharmaceuticals (NASDAQ: CRBP) will release results from its Phase 1a single ascending dose (SAD) and multiple ascending dose (MAD) study of oral CB1 inverse agonist CRB-913 before market open on Thursday, December 11, 2025.

Rhea-AI Summary

Corbus Pharmaceuticals (NASDAQ: CRBP) will release results from its Phase 1a single ascending dose (SAD) and multiple ascending dose (MAD) study of oral CB1 inverse agonist CRB-913 before market open on Thursday, December 11, 2025.

The company will host a conference call and live webcast at 8:00 am ET the same day to review the Phase 1a safety and tolerability data; a replay will be available on the Corbus website.

Argus Dec 11 session

-5.65% close to close Open Argus

Details

News Market Reaction – CRBP

On Dec 11, the first trading day after this news, CRBP closed 5.65% below the previous close.

Data tracked by StockTitan Argus for the Dec 11 session.

Key Figures

Data call time: 8:00 am ET Readout date: December 11, 2025

Data call time

8:00 am ET

Conference call and webcast to review Phase 1a CRB-913 data

Readout date

December 11, 2025

Phase 1a SAD/MAD CRB-913 results planned before market open

Historical Context

5 past events · Latest: Nov 12

5 events

1. Nov 12

   Earnings and update

   24h Move

   +7.4%

   Q3 2025 report, CRB-701 data, funding runway and upcoming CRB-913 readout.

2. Nov 06

   Investor conferences

   24h Move

   -4.2%

   Participation in three investor conferences with webcasted presentations and meetings.

3. Oct 31

   Public offering priced

   24h Move

   -26.1%

   Pricing of equity and pre-funded warrant offering to raise about $75M.

4. Oct 30

   Offering proposed

   24h Move

   -2.5%

   Announcement of proposed underwritten public offering and potential overallotment.

5. Oct 14

   Conference clinical data

   24h Move

   -0.4%

   Plan to present updated CRB-701 Phase 1/2 data at ESMO 2025.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

phase 1a, single ascending dose, multiple ascending dose, inverse agonist

4 terms

phase 1a medical

"results of its Phase 1a single ascending dose (SAD) and multiple ascending dose"

Phase 1a is the initial part of a human clinical trial where a new drug or therapy is given to a small group of people for the first time to check safety, how the body handles it, and to identify appropriate dosing. Investors watch phase 1a like a vehicle's first test drive: clear safety and predictable behavior reduce risk and unlock value by allowing larger, more expensive trials to proceed and by increasing the chance of regulatory progress.

single ascending dose medical

"Phase 1a single ascending dose (SAD) and multiple ascending dose (MAD) study"

A single ascending dose is a method used in testing new medicines where small amounts are given to participants, gradually increasing each time to find the safest and most effective dose. For investors, it provides important information about a drug’s safety and potential, helping gauge the progress and prospects of a pharmaceutical development.

multiple ascending dose medical

"single ascending dose (SAD) and multiple ascending dose (MAD) study of CRB-913"

A multiple ascending dose is a method used in testing new medicines where small groups of people receive gradually larger amounts of the drug over time. This approach helps researchers find the safest and most effective dose without causing too many side effects. For investors, it signals ongoing steps in drug development that can impact a company's potential success or approval prospects.

inverse agonist medical

"Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity"

An inverse agonist is a type of drug that binds to a biological receptor and reduces the receptor’s natural, ongoing activity, producing the opposite effect of what an activating drug would do. For investors, this matters because inverse agonists can treat conditions where reducing baseline receptor activity is beneficial, potentially creating distinct clinical uses, regulatory pathways, and market value compared with drugs that merely block or activate the same target; think of it as a brake that not only stops a moving car but pushes it slightly backward.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Company will host conference call and live webcast to review and discuss the data at 8:00 am ET

NORWOOD, Mass., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical stage company focused on oncology and obesity, announced the Company’s plan to release results of its Phase 1a single ascending dose (SAD) and multiple ascending dose (MAD) study of CRB-913 prior to the market open on Thursday, December 11, 2025. Corbus will host a conference call and live webcast the same day at 8:00 am ET to review and discuss the Phase 1a data.

To register for the webcast, click here . A replay will be available on the Corbus website.

About CRB-913
CRB-913 is an oral small molecule inverse agonist of the G-protein Coupled Receptor (GPCR) cannabinoid type-1 (CB1). This is a recognized mechanism of action for weight loss, but the first generation of experimental drugs in this class was abandoned due to potential neuropsychiatric adverse event risks. CRB-913 is a highly peripherally restricted CB1 inverse agonist designed to have reduced brain penetration. Preclinical models have shown CRB-913 to be 15-fold less brain-penetrant than monlunabant (another experimental CB1 inverse agonist) and to have 50 times lower brain:plasma ratio than rimonabant (an extensively studied first-generation CB1 inverse agonist).

About Corbus
Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage company focused on oncology and obesity and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well-understood biological pathways. Corbus’ pipeline includes CRB-701, a next-generation antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFβ expressed on cancer cells, and CRB-913, a highly peripherally restricted CB1 receptor inverse agonist for the treatment of obesity. Corbus is headquartered in Norwood, Massachusetts. For more information on Corbus, visit corbuspharma.com. Connect with us on X, LinkedIn and Facebook.

Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s trial results, product development, clinical and regulatory timelines, including timing for completion of trials and presentation of data, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions.

These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors on our operations, clinical development plans and timelines, which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

All product names, logos, brands and company names are trademarks or registered trademarks of their respective owners. Their use does not imply affiliation or endorsement by these companies.

INVESTOR CONTACTS:

Sean Moran
Chief Financial Officer
Corbus Pharmaceuticals
smoran@corbuspharma.com

Dan Ferry
Managing Director
LifeSci Advisors, LLC
daniel@lifesciadvisors.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Corbus (CRBP) release Phase 1a CRB-913 results?

Corbus will release Phase 1a SAD and MAD results before market open on December 11, 2025.

What time is the Corbus (CRBP) conference call and webcast for CRB-913 data?

The conference call and live webcast are scheduled for 8:00 am ET on December 11, 2025.

What does the Phase 1a study of CRB-913 include for CRBP?

The Phase 1a study includes single ascending dose (SAD) and multiple ascending dose (MAD) cohorts assessing CRB-913.

How can investors access the Corbus (CRBP) CRB-913 webcast and replay?

Investors can register for the live webcast via the company site and access a replay on the Corbus website after the call.

Will Corbus (CRBP) discuss safety and tolerability in the December 11, 2025 call?

Yes, the company will review and discuss the Phase 1a data, which covers safety and tolerability findings.